Actinogen Medical Limited (ATGGF)
OTC PINK OTC PINK Primary Summary
ATGGF Chart
Actinogen Medical Limited (ATGGF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Actinogen Medical Limited ever had a stock split?
Actinogen Medical Limited Profile
| Biotechnology Industry | Healthcare Sector | Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. CEO | OTC PINK Exchange | AU000000ACW3 ISIN |
| US Country | - Employees | - Last Dividend | 27 Sep 2023 Last Split | 15 Oct 2007 IPO Date |
Overview
Actinogen Medical Limited is an Australian-based biotechnology firm focused on the development of novel therapeutics for neurological and neuropsychiatric conditions that are linked to dysregulated brain cortisol levels. Since its inception in 1999, the company has established itself as a pioneer in targeting the complex mechanisms underlying these conditions. Originally founded as Actinogen Limited, the organization underwent a significant rebranding to Actinogen Medical Limited in November 2015, a move that reflects its intensified focus on medical applications of its research. Headquartered in Sydney, Australia, Actinogen Medical is at the forefront of biotechnological innovation, leveraging its scientific expertise to address some of the most challenging mental health and neurological disorders facing the global population today.
Products and Services
Xanamem
An innovative therapeutic candidate, Xanamem is at the core of Actinogen Medical's product pipeline. Designed as an inhibitor of the 11ß-HSD1 enzyme, Xanamem is pivotal in the company's approach to addressing conditions related to abnormal cortisol levels within the brain. Currently undergoing Phase 2 clinical trials, Xanamem has shown promise in a variety of applications, including:
- Central Nervous System (CNS) Engagement: Xanamem's ability to achieve target engagement within the CNS is crucial for its effectiveness across a range of disorders.
- Depression with Cognitive Impairment: Leveraging its unique mechanism of action, Xanamem aims to address the challenging overlap between depressive symptoms and cognitive decline.
- Alzheimer's Disease: Xanamem's potential to modulate cortisol levels offers a novel approach to Alzheimer’s disease, a condition with few effective treatments.
- Anxiety, Sleep, and Behavioral Problems in Fragile X Syndrome: The broad therapeutic applicability of Xanamem extends to managing anxiety, sleep disturbances, and behavioral issues associated with Fragile X syndrome.
This wide-ranging potential establishes Xanamem as a significant asset in Actinogen Medical’s ambition to provide innovative solutions for complex neuropsychiatric and neurological diseases.
